Skip to Content

Invega Trinza Approval History

FDA Approved: Yes (First approved May 18, 2015)
Brand name: Invega Trinza
Generic name: paliperidone palmitate
Dosage form: Extended-Release Injectable Suspension
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia

Invega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia.

Development History and FDA Approval Process for Invega Trinza

DateArticle
May 19, 2015Approval FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide